{"schemaVersion":"peptidescanner-peptide-evidence-feed/v1","canonicalUrl":"https://peptidescanner.com/feeds/peptides/carfilzomib.json","peptide":{"slug":"carfilzomib","name":"Carfilzomib","url":"https://peptidescanner.com/peptides/carfilzomib/"},"release":{"label":"Beta · 17 Nov 2026","reviewedAt":"2026-11-17"},"entryCount":62,"entries":[{"objectId":"story:clinicaltrials-gov-nct03606577-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-17","title":"ClinicalTrials.gov record NCT03606577","domain":"Clinical trials","dateInSource":"2026-11-12","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03606577-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03606577-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03606577-carfilzomib-v1","contentSha256":"aa24d739a85f1564c8746d0d9a1795948f17ed520151a38dd612625dc9ddf3e3"},{"objectId":"story:clinicaltrials-gov-nct06152575-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-17","title":"ClinicalTrials.gov record NCT06152575","domain":"Clinical trials","dateInSource":"2026-11-12","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct06152575-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct06152575-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct06152575-carfilzomib-v1","contentSha256":"aac7b8198d7c9c567066cb5f353a226fbe8432e66ac1f73c6c5f8b59d24c99aa"},{"objectId":"story:clinicaltrials-gov-nct07555938-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-17","title":"ClinicalTrials.gov record NCT07555938","domain":"Clinical trials","dateInSource":"2026-11-10","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct07555938-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07555938-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct07555938-carfilzomib-v1","contentSha256":"d1b74ce676f2afc895e6ce0965b8b8a01475613e536724995614379666d00c80"},{"objectId":"story:clinicaltrials-gov-nct07715903-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-17","title":"ClinicalTrials.gov record NCT07715903","domain":"Clinical trials","dateInSource":"2026-11-16","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct07715903-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07715903-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct07715903-carfilzomib-v1","contentSha256":"a4cc2f5646092ae516a0a774bc5099e256b0f6d101aac832d9e504c2dcf977a6"},{"objectId":"story:fda-drugs-anda209330:v1","state":"current","stateChangedAt":"2026-11-17","title":"Drugs@FDA application ANDA209330","domain":"Regulatory","dateInSource":"2021-06-11","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/fda-drugs-anda209330/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209330-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#fda-drugs-anda209330-v1","contentSha256":"6cef73b07697a9d0b14add378306364ecc5b19bf06461d8622857e6f0598225c"},{"objectId":"story:fda-drugs-anda209422:v1","state":"current","stateChangedAt":"2026-11-17","title":"Drugs@FDA application ANDA209422","domain":"Regulatory","dateInSource":"2019-09-09","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/fda-drugs-anda209422/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209422-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#fda-drugs-anda209422-v1","contentSha256":"0994d738e2a8810c270f13d8e3d9d976803827f834bd68051c6d2e3068d7be64"},{"objectId":"story:fda-drugs-anda209425:v1","state":"current","stateChangedAt":"2026-11-17","title":"Drugs@FDA application ANDA209425","domain":"Regulatory","dateInSource":"2020-03-16","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/fda-drugs-anda209425/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209425-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#fda-drugs-anda209425-v1","contentSha256":"9db3da6aaa65cbdcdd79268bbe0e82bd232fb5285507ae1518adb23b23de64b1"},{"objectId":"story:fda-drugs-anda209526:v1","state":"current","stateChangedAt":"2026-11-17","title":"Drugs@FDA application ANDA209526","domain":"Regulatory","dateInSource":"2026-07-20","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/fda-drugs-anda209526/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209526-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#fda-drugs-anda209526-v1","contentSha256":"ce792e6ab3656d88d6857bfd5c4d315d20f6760b6045e1fc1f84b2a0e5dac1df"},{"objectId":"story:fda-drugs-anda211185:v1","state":"current","stateChangedAt":"2026-11-17","title":"Drugs@FDA application ANDA211185","domain":"Regulatory","dateInSource":"2020-03-20","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/fda-drugs-anda211185/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda211185-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#fda-drugs-anda211185-v1","contentSha256":"496b32b3ca323bea52622fba29df8ca89cd815cd559710b82c9c87cda100c924"},{"objectId":"story:fda-drugs-nda202714:v1","state":"current","stateChangedAt":"2026-11-17","title":"Drugs@FDA application NDA202714","domain":"Regulatory","dateInSource":"2012-07-20","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/fda-drugs-nda202714/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-nda202714-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#fda-drugs-nda202714-v1","contentSha256":"de8df92a18e36c501f7e2f28b124c280186c719226f65921fe667fef74d33002"},{"objectId":"story:federal-register-2012-10154:v1","state":"current","stateChangedAt":"2026-11-17","title":"Federal Register notice 2012-10154","domain":"Regulatory","dateInSource":"2012-04-27","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/federal-register-2012-10154/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2012-10154-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#federal-register-2012-10154-v1","contentSha256":"2418e27b7730cad00dc493f4ace3bafaca21d97df7c30e93a92a7d632d645571"},{"objectId":"story:federal-register-2014-11175:v1","state":"current","stateChangedAt":"2026-11-17","title":"Federal Register notice 2014-11175","domain":"Regulatory","dateInSource":"2014-05-15","publishedAt":"2026-11-17","humanUrl":"https://peptidescanner.com/stories/federal-register-2014-11175/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2014-11175-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#federal-register-2014-11175-v1","contentSha256":"e31c06e64a911dd0d4688774ad7329d4d8b86b08da42d3c0d9e7c17306e7b8a8"},{"objectId":"story:clinicaltrials-gov-nct01080391-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01080391","domain":"Clinical trials","dateInSource":"2022-09-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01080391-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01080391-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01080391-carfilzomib-v1","contentSha256":"73da0d70762a5429ecfa052e03d0280076e2091cdb4fe2138c93653b448ff3cf"},{"objectId":"story:clinicaltrials-gov-nct01302392-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01302392","domain":"Clinical trials","dateInSource":"2017-05-02","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01302392-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01302392-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01302392-carfilzomib-v1","contentSha256":"3ecfe945ffc7ed5bd8d9a9de93f522b0cf77fcc1e7ed3e66056473071177f458"},{"objectId":"story:clinicaltrials-gov-nct01559935-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01559935","domain":"Clinical trials","dateInSource":"2026-09-29","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01559935-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01559935-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01559935-carfilzomib-v1","contentSha256":"53507780b55a8f47cb1fc70cfa23884f5accb31b5db480b21dcbfcecaba8d28c"},{"objectId":"story:clinicaltrials-gov-nct01568866-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01568866","domain":"Clinical trials","dateInSource":"2022-11-14","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01568866-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01568866-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01568866-carfilzomib-v1","contentSha256":"c435d3438487cbfe7f10a8d362446dafd53ae0a03a340bd4f4af2f841bb5d97a"},{"objectId":"story:clinicaltrials-gov-nct01572480-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01572480","domain":"Clinical trials","dateInSource":"2026-03-10","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01572480-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01572480-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01572480-carfilzomib-v1","contentSha256":"0c5bdfba57bcdaa9901641dc1d43d74a8bcac3edf7292ad8a712107b22eb72ce"},{"objectId":"story:clinicaltrials-gov-nct01813227-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01813227","domain":"Clinical trials","dateInSource":"2026-04-03","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01813227-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01813227-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01813227-carfilzomib-v1","contentSha256":"d66abf2a3130d59ccf3f8f74fbfd75d8868a72cc0aeb24821c130ff5f967cfcb"},{"objectId":"story:clinicaltrials-gov-nct01816971-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01816971","domain":"Clinical trials","dateInSource":"2026-04-21","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01816971-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01816971-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01816971-carfilzomib-v1","contentSha256":"7b0d46cf38b7ccf1b6c3e4147cb6459849d9914d905f6c4c035d8bcbe70e9be6"},{"objectId":"story:clinicaltrials-gov-nct01818752-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT01818752","domain":"Clinical trials","dateInSource":"2019-08-26","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct01818752-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01818752-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct01818752-carfilzomib-v1","contentSha256":"9239a26660fc305b6691ed6e7c2a929e6495e7855dfe72c9b0aa082fa2d9df67"},{"objectId":"story:clinicaltrials-gov-nct02412878-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT02412878","domain":"Clinical trials","dateInSource":"2022-09-23","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct02412878-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02412878-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct02412878-carfilzomib-v1","contentSha256":"c157754d2066966e4b07ee40d722bbea33640881250f6fe34c6fccaffacd304f"},{"objectId":"story:clinicaltrials-gov-nct02773030-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT02773030","domain":"Clinical trials","dateInSource":"2026-03-20","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct02773030-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02773030-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct02773030-carfilzomib-v1","contentSha256":"a1a43eeeaaf90192d7becfe18038bb54e1b3e694af32441c776658c29aee40d8"},{"objectId":"story:clinicaltrials-gov-nct02937571-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT02937571","domain":"Clinical trials","dateInSource":"2025-11-20","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct02937571-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02937571-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct02937571-carfilzomib-v1","contentSha256":"70cfa150736138ee948b701de755fbaccdd8451f3ba195ebd099df84f1c876ba"},{"objectId":"story:clinicaltrials-gov-nct02969837-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT02969837","domain":"Clinical trials","dateInSource":"2026-01-16","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct02969837-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02969837-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct02969837-carfilzomib-v1","contentSha256":"d3732db5f19de6897f80ae6fc0e0328f3536261342903552282d4e1eb804d194"},{"objectId":"story:clinicaltrials-gov-nct03029234-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03029234","domain":"Clinical trials","dateInSource":"2022-05-25","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03029234-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03029234-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03029234-carfilzomib-v1","contentSha256":"6fed0f25a208f667484f48e8cacc311b217a5e07aecf3f41864a77412549fccd"},{"objectId":"story:clinicaltrials-gov-nct03158688-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03158688","domain":"Clinical trials","dateInSource":"2025-05-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03158688-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03158688-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03158688-carfilzomib-v1","contentSha256":"6e779b0edbf58df888b2cbb8188e61ab2d0517cc0a17bf735e10ae2cb7e2e135"},{"objectId":"story:clinicaltrials-gov-nct03275285-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03275285","domain":"Clinical trials","dateInSource":"2026-02-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03275285-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03275285-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03275285-carfilzomib-v1","contentSha256":"46765c1bcdd810e0bfb946973c034271438c4fb744342afff8b10025d3007234"},{"objectId":"story:clinicaltrials-gov-nct03290950-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03290950","domain":"Clinical trials","dateInSource":"2026-05-29","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03290950-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03290950-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03290950-carfilzomib-v1","contentSha256":"15d9b201fbb3f33feee203c9545fd81e2e0ca143abcfcc758f6fedc6021920b5"},{"objectId":"story:clinicaltrials-gov-nct03412565-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03412565","domain":"Clinical trials","dateInSource":"2025-04-29","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03412565-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03412565-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03412565-carfilzomib-v1","contentSha256":"402f7c79afcd85bd8517ca20d5674663e689fe034314c6ce2438e3db2dcdeb67"},{"objectId":"story:clinicaltrials-gov-nct03416374-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03416374","domain":"Clinical trials","dateInSource":"2022-09-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03416374-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03416374-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03416374-carfilzomib-v1","contentSha256":"1b2ece425e53d16bf0bb444d4f796a981ff82365e85e667e9de04c560da1ebe2"},{"objectId":"story:clinicaltrials-gov-nct03859427-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03859427","domain":"Clinical trials","dateInSource":"2024-08-13","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03859427-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03859427-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03859427-carfilzomib-v1","contentSha256":"4902cb7d34600831cc7b8dc12026e95a1ccb347b44b02779388326d0a8d878c3"},{"objectId":"story:clinicaltrials-gov-nct03934684-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT03934684","domain":"Clinical trials","dateInSource":"2026-05-11","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct03934684-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03934684-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct03934684-carfilzomib-v1","contentSha256":"b51e42587f0928b7053ac24e533cba1a97a7cb4ee5dd15ed3b941835f3b15e54"},{"objectId":"story:clinicaltrials-gov-nct04191616-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT04191616","domain":"Clinical trials","dateInSource":"2025-09-04","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04191616-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04191616-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct04191616-carfilzomib-v1","contentSha256":"b6641954d77cbc53836759cc57918d78211d7faef254a15743bc758d0966338c"},{"objectId":"story:clinicaltrials-gov-nct04430894-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT04430894","domain":"Clinical trials","dateInSource":"2026-10-06","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04430894-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04430894-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct04430894-carfilzomib-v1","contentSha256":"3870724c739142723535356ecc4661b6c6155d3479db9577bd47d81f151a7e28"},{"objectId":"story:clinicaltrials-gov-nct04756401-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT04756401","domain":"Clinical trials","dateInSource":"2026-09-15","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04756401-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04756401-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct04756401-carfilzomib-v1","contentSha256":"08c26e2411876def405c9b65e04aac5068e6489fa4cf1a1fc293d4f71e9e8213"},{"objectId":"story:clinicaltrials-gov-nct04925193-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT04925193","domain":"Clinical trials","dateInSource":"2026-10-02","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct04925193-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04925193-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct04925193-carfilzomib-v1","contentSha256":"d0a38baeda8e0f1ec093e7055a06c8b88c97ae394309b9cda0a62d1121e7bcdd"},{"objectId":"story:clinicaltrials-gov-nct05497804-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"ClinicalTrials.gov record NCT05497804","domain":"Clinical trials","dateInSource":"2026-11-02","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/clinicaltrials-gov-nct05497804-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct05497804-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#clinicaltrials-gov-nct05497804-carfilzomib-v1","contentSha256":"34dd1b3f1317688ae3a4929074692000ddb4914958480872f16f730a6db10b40"},{"objectId":"story:pubmed-pmid-34647444-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.","domain":"Literature metadata","dateInSource":"2026-09-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-34647444-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34647444-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-34647444-carfilzomib-v1","contentSha256":"5dd56e36251adaedc5bce66ef16384707e0ca7a535e876655659309436627579"},{"objectId":"story:pubmed-pmid-34774221-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with…","domain":"Literature metadata","dateInSource":"2022-01-10","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-34774221-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34774221-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-34774221-carfilzomib-v1","contentSha256":"1278ff22fc308ce121d9ea7721a3e0afcb87a90326a28e622f2e79f4b47d69df"},{"objectId":"story:pubmed-pmid-35578151-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.","domain":"Literature metadata","dateInSource":"2026-10-29","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-35578151-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-35578151-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-35578151-carfilzomib-v1","contentSha256":"3da7d0f0a50f425ea1641c02841588f23642ffbd9a9905cd26249161d07b863f"},{"objectId":"story:pubmed-pmid-36073950-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-36073950-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36073950-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-36073950-carfilzomib-v1","contentSha256":"e35b41541f612a5ed9b1b4c611d3da067fd63ec3b2ef3603bd4ab3cab7114842"},{"objectId":"story:pubmed-pmid-36372355-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-36372355-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36372355-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-36372355-carfilzomib-v1","contentSha256":"766adbc2e9f70d044cb76f043719d062891ec5832da8920c83d79d5931c13031"},{"objectId":"story:pubmed-pmid-36375132-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-36375132-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36375132-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-36375132-carfilzomib-v1","contentSha256":"5e0eb4572e5c523943bb7c405c7b3d141a1a4d2482fe8aaaa162c5370862fe00"},{"objectId":"story:pubmed-pmid-36529145-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…","domain":"Literature metadata","dateInSource":"2026-11-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-36529145-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36529145-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-36529145-carfilzomib-v1","contentSha256":"fc1cd7155b0c14120fbfbad9119d69d35fb30147389d1692e6c87576f6b71644"},{"objectId":"story:pubmed-pmid-36642080-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a r…","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-36642080-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36642080-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-36642080-carfilzomib-v1","contentSha256":"60d3db81432499949a3ea7431b12c2e71942b35a745d56149e6c24f3c2d8744a"},{"objectId":"story:pubmed-pmid-36763537-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-36763537-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36763537-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-36763537-carfilzomib-v1","contentSha256":"bf63295274c789197f381dc85ed8f3d5c7f9ddb11f516b0485f370ba2e59cdd1"},{"objectId":"story:pubmed-pmid-37479547-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-37479547-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37479547-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-37479547-carfilzomib-v1","contentSha256":"ea78ba796121cb5cbd5685567bb8042c8a411947a4208d7775c8bbca31956afb"},{"objectId":"story:pubmed-pmid-37584290-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.","domain":"Literature metadata","dateInSource":"2024-10-23","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-37584290-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37584290-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-37584290-carfilzomib-v1","contentSha256":"b0e854055eb75138ec10822b93bcc72182574207a7af0fc0a636d8b48a2c62b5"},{"objectId":"story:pubmed-pmid-37632592-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell L…","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-37632592-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37632592-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-37632592-carfilzomib-v1","contentSha256":"b61f89ae58b535b312c17e58fb71227e5268c2da0a0606dfde3885d09d36fb09"},{"objectId":"story:pubmed-pmid-37691005-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomi…","domain":"Literature metadata","dateInSource":"2026-01-27","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-37691005-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37691005-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-37691005-carfilzomib-v1","contentSha256":"9f8558cba04e8b9fb91a55933b5e06e092ae7003c43f121317544a1f3012edca"},{"objectId":"story:pubmed-pmid-37717583-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.","domain":"Literature metadata","dateInSource":"2026-03-24","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-37717583-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37717583-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-37717583-carfilzomib-v1","contentSha256":"184646cb29baa4345741d075a546021f3b53b771d304f322dd0770d27b9c15fa"},{"objectId":"story:pubmed-pmid-38747414-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide al…","domain":"Literature metadata","dateInSource":"2024-09-14","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-38747414-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38747414-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-38747414-carfilzomib-v1","contentSha256":"434ee580f007a9a4c5f694fb35da2548e20039a34158de0ae1dfc715f3b49ef8"},{"objectId":"story:pubmed-pmid-38811560-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.","domain":"Literature metadata","dateInSource":"2024-11-07","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-38811560-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38811560-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-38811560-carfilzomib-v1","contentSha256":"92f82085eedef61f45057c7a0b8e5298e448acbbcb44314c7ed93148aece56a1"},{"objectId":"story:pubmed-pmid-38938122-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.","domain":"Literature metadata","dateInSource":"2025-01-30","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-38938122-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38938122-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-38938122-carfilzomib-v1","contentSha256":"c1a51c126c50acf91af1932d4c54878010df0cae6fdb3f34d6569fd949067a95"},{"objectId":"story:pubmed-pmid-39576965-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.","domain":"Literature metadata","dateInSource":"2025-06-03","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-39576965-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39576965-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-39576965-carfilzomib-v1","contentSha256":"01c2a2ffd52c7cb8ae90c65dffdebbc8c23bdc2d548c204254d17c82ff0311bc"},{"objectId":"story:pubmed-pmid-39638553-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.","domain":"Literature metadata","dateInSource":"2025-06-05","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-39638553-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39638553-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-39638553-carfilzomib-v1","contentSha256":"88d3482e39f28d20766a97955f37b3704e0c266e936b1578a992c25b9b890279"},{"objectId":"story:pubmed-pmid-40213696-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management.","domain":"Literature metadata","dateInSource":"2025-04-12","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-40213696-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40213696-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-40213696-carfilzomib-v1","contentSha256":"6c39d2d78348eb444a2a23708bdccfd8b33366b776d296654843e5d9a653ff80"},{"objectId":"story:pubmed-pmid-40397818-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.","domain":"Literature metadata","dateInSource":"2026-11-13","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-40397818-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40397818-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-40397818-carfilzomib-v1","contentSha256":"3a7790274ac6e40beafde3ef3a52bfe095da96ff92e5e539b8e90fdbb8220f55"},{"objectId":"story:pubmed-pmid-40672881-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.","domain":"Literature metadata","dateInSource":"2025-09-06","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-40672881-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40672881-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-40672881-carfilzomib-v1","contentSha256":"d3c972d9b4029e1b47f650cf75dbc95a61b9644b3b1b337baa0c4098522c1c6b"},{"objectId":"story:pubmed-pmid-41134506-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.","domain":"Literature metadata","dateInSource":"2026-10-09","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-41134506-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41134506-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-41134506-carfilzomib-v1","contentSha256":"44d6021079736ca2e392e1b449b7b9bf8eb2801b5827b551fafdf2f94007eea5"},{"objectId":"story:pubmed-pmid-41719502-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.","domain":"Literature metadata","dateInSource":"2026-09-26","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-41719502-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41719502-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-41719502-carfilzomib-v1","contentSha256":"f0c34666e38af50841af889b983dfcf7b3c83dde35f167a86d920f5c3769316e"},{"objectId":"story:pubmed-pmid-41942646-carfilzomib:v1","state":"current","stateChangedAt":"2026-11-16","title":"Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.","domain":"Literature metadata","dateInSource":"2026-08-13","publishedAt":"2026-11-16","humanUrl":"https://peptidescanner.com/stories/pubmed-pmid-41942646-carfilzomib/","jsonUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41942646-carfilzomib-v1","markdownUrl":"https://peptidescanner.com/evidence/v1/peptides/carfilzomib.md#pubmed-pmid-41942646-carfilzomib-v1","contentSha256":"c9281be97d88a00fd4192d6ee0840e11ba47ba24fe22d5ea61c764070ed3d17d"}]}
